Accelerated Approval pathway for our ST-920 gene therapy product candidate for the treatment of Fabry disease.

Uncategorized

Sangamo Appoints Scott Willoughby as Senior Vice President, General Counsel and Corporate Secretary

Scott Willoughby serves as Sangamo’s Senior Vice President, General Counsel and Corporate Secretary acting as lead attorney for the company and advising the Chief Executive Officer, Board of Directors and other members of the executive leadership team on legal and business matters. He brings more than 20 years of expertise in senior legal and compliance roles at global public and private companies across multiple industries.

Scott Willoughby Quote

“I’m thrilled and grateful to join Sangamo’s executive leadership team at a time when we have so many opportunities ahead of us to demonstrate the promise of genomic medicine for patients. Working alongside such talented innovators is immensely inspiring,” Willoughby shared.

Mr. Willoughby joined Sangamo in March 2020 as Vice President and Head of Corporate Law. Since joining the company, he has been an active member of the Legal Leadership Team where he has helped lead the legal and compliance functions. Prior to joining Sangamo, he served as Vice President-Deputy General Counsel, Assistant Corporate Secretary and Head of Corporate Law at Achaogen, a biotechnology company developing innovative antibiotics. Earlier in his career he held several senior counsel roles where he built his expertise in corporate governance, SEC reporting, corporate finance, compliance, M&A and transactions.

Mr. Willoughby received a B.A. and J.D. from the University of California, Berkeley.